Acadia, Stoke to develop RNA-based treatments for neurodevelopmental diseases
The collaboration is expected to allow Stoke to receive potential milestone payments of up to $907m
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
11 Jan 22
The collaboration is expected to allow Stoke to receive potential milestone payments of up to $907m
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
07 Jan 22
The acquisition of Exelead, a full-service contract development and manufacturing organisation focused on Lipid Nanoparticle formulations, is expected…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
22 Dec 21
The acquisition of Amunix will enable Sanofi to discover and develop advanced T-cell engagers (TCE) and cytokine medicines…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
15 Dec 21
The acquisition is expected to expand CSL’s offering across a portfolio focused on renal disease, and iron deficiency…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
14 Dec 21
Arena is a clinical-stage pharmaceutical company involved in the development of potential therapies for the treatment of several…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
09 Dec 21
The acquisition will enable Thermo Fisher to provide a complete suite of discovery, clinical trial logistics, development and…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
08 Dec 21
The transaction will enable Alvotech to further invest in its platform and portfolio, and support its goal of…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
06 Dec 21
The expanded EUA was based on safety and efficacy data of paediatric and infant patients in Phase 2/3…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
01 Dec 21
According to the British drugmaker, Lynparza is the first medicine targeting BRCA mutations that showed clinical benefit in…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
26 Nov 21
With the divestments of UK oral liquid products, Essential Pharma expects to streamline its portfolio and advance its…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates